Journal
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Volume 75, Issue 6, Pages 526-529Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FJC.0000000000000840
Keywords
angiotensin converting enzyme 2; coronavirus disease-2019; severe acute respiratory syndrome coronavirus-2019; renin-angiotensin-aldosterone system; angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; mineralocorticoid receptor antagonist
Ask authors/readers for more resources
Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). Preclinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. In addition, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology, as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available